Adicet Bio
Adicet Bio is a biotechnology company specializing in the development of allogeneic, genetically modified gamma delta T cells for treating autoimmune diseases and cancer, with offices in Redwood City, CA, and Boston, MA.
About Adicet Bio
Adicet Bio develops allogeneic off-the-shelf genetically modified gamma delta T cells for the treatment of autoimmune diseases and cancer. The company's advanced immune cell therapies are designed using gamma delta T cells to create a new generation of therapy that is believed to offer significant advantages over traditional methods.
Technology and Innovation
Adicet Bio employs gamma delta T cells engineered with chimeric antigen receptors (CARs) to enhance selective tumor targeting. Their proprietary cell platform is utilized for activating, engineering, and expanding these gamma delta T cells, which are shown to have superior potential in both hematological cancers and solid tumors compared to alpha beta T cells. This approach also minimizes the risk of Graft vs Host Disease due to the MHC-independent manner of tumor killing.
Office Locations
Adicet Bio operates offices in Redwood City, California, and Boston, Massachusetts. These strategic locations support the company's research and development, as well as its operational and clinical activities.
Industry Participation
In 2024, Adicet Bio participated in the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting and the Canaccord Genuity Horizons in Oncology Virtual Conference. These events reflect the company's active involvement in the scientific community and commitment to advancing research in gene and cell therapy.